Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0BSWTQ)
| ADC Name |
QLS5316
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
QLS5316
Click to Show/Hide
|
|||||
| Organization |
Qilu Pharmaceutical (Originator)
|
|||||
| Drug Status |
Phase 1
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Antibody Name |
Anti-EGFR/c-Met bsAb
|
Antibody Info | ||||
| Antigen Name |
Hepatocyte growth factor receptor (MET); Epidermal growth factor receptor (EGFR)
|
Antigen Info | ||||
| Payload Name |
QLS6916
|
Payload Info | ||||
| Payload Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
A cleavable linker
|
Linker Info | ||||
| Conjugate Type |
Undisclosed
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
| Disease Name | Phase 1 | Phase 2 | Phase 3 | Approved |
|---|---|---|---|---|
| Gastroesophageal junction adenocarcinoma | ||||
| Gastric cancer | ||||
| Colorectal cancer | ||||
| Lung cancer | ||||
| Head and neck cancer | ||||
| Unspecific solid tumor |